Hmdb loader

HMDBP00169 (Amine oxidase [flavin-containing] A) Metabolite Associations

Displaying metabolite protein links 26 - 50 of 68 in total
HMDB ID Name CAS NumberStructureFormula Average Mass
Monoisotopic Mass 		References
HMDB0015563Pargyline555-57-7ThumbC11H13N159.2276
159.104799421
  1. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
  2. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841 ]
  3. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422 ]
  4. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646 ]
  5. Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T: Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J Neural Transm Suppl. 1998;52:39-48. [PubMed:9564606 ]
  6. Fuentes JA, Ordaz A, Neff NH: Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7. [PubMed:477738 ]
HMDB0000303Tryptamine61-54-1ThumbC10H12N2160.2157
160.100048394		Not Available
HMDB00040774,6-Dihydroxyquinoline3517-61-1ThumbC9H7NO2161.1574
161.047678473		Not Available
HMDB0060289Quinoline-4,8-diolThumbC9H7NO2161.1574
161.047678473		Not Available
HMDB0001934Nicotine54-11-5ThumbC10H14N2162.2316
162.115698458
  1. Lewis AJ, Truman P, Hosking MR, Miller JH: Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type. Tob Control. 2012 Jan;21(1):39-43. doi: 10.1136/tc.2010.040287. Epub 2011 Jun 2. [PubMed:21636610 ]
  2. Leroy C, Bragulat V, Berlin I, Gregoire MC, Bottlaender M, Roumenov D, Dolle F, Bourgeois S, Penttila J, Artiges E, Martinot JL, Trichard C: Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone. J Clin Psychopharmacol. 2009 Feb;29(1):86-8. doi: 10.1097/JCP.0b013e31819e98f. [PubMed:19142115 ]
HMDB0001943Pseudoephedrine90-82-4ThumbC10H15NO165.2322
165.115364107		Not Available
HMDB0005175Homovanillin5703-24-2ThumbC9H10O3166.1739
166.062994186		Not Available
HMDB0002182Phenylephrine59-42-7ThumbC9H13NO2167.205
167.094628665		Not Available
HMDB00000223-Methoxytyramine554-52-9ThumbC9H13NO2167.205
167.094628665		Not Available
HMDB00062423,4-Dihydroxymandelaldehyde13023-73-9ThumbC8H8O4168.1467
168.042258744		Not Available
HMDB0000216Norepinephrine51-41-2ThumbC8H11NO3169.1778
169.073893223		Not Available
HMDB00040735-Hydroxyindoleacetaldehyde1892-21-3ThumbC10H9NO2175.184
175.063328537		Not Available
HMDB0000259Serotonin50-67-9ThumbC10H12N2O176.2151
176.094963016		Not Available
HMDB00602813-HydroxykynurenamineThumbC9H12N2O2180.2038
180.089877638		Not Available
HMDB00040765-Hydroxykynurenamine708-23-6ThumbC9H12N2O2180.2038
180.089877638		Not Available
HMDB00040613-Methoxy-4-hydroxyphenylglycolaldehyde17592-23-3ThumbC9H10O4182.1733
182.057908808		Not Available
HMDB0000819Normetanephrine97-31-4ThumbC9H13NO3183.2044
183.089543287		Not Available
HMDB0000068Epinephrine51-43-4ThumbC9H13NO3183.2044
183.089543287		Not Available
HMDB0015171Selegiline14611-51-9ThumbC13H17N187.2808
187.136099549
  1. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
  2. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841 ]
  3. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422 ]
  4. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646 ]
HMDB00040955-Methoxytryptamine608-07-1ThumbC11H14N2O190.2417
190.11061308		Not Available
HMDB0004369N-Methylserotonin1134-01-6ThumbC11H14N2O190.2417
190.11061308		Not Available
HMDB0004063Metanephrine5001-33-2ThumbC10H15NO3197.231
197.105193351		Not Available
HMDB0015045Zonisamide68291-97-4ThumbC8H8N2O3S212.226
212.025562822
  1. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722 ]
  2. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y: Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995 Nov;22(3):193-205. [PubMed:8991786 ]
HMDB0014752Furazolidone67-45-8ThumbC8H7N3O5225.16
225.038570337
  1. Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758 ]
  2. Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364 ]
  3. Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659 ]
HMDB0015377Isocarboxazid59-63-2ThumbC12H13N3O2231.2505
231.100776675
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Thase ME, Trivedi MH, Rush AJ: MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219. [PubMed:7612154 ]
  3. Kettler R, Da Prada M, Burkard WP: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl. 1990;360:101-2. [PubMed:2248058 ]
Displaying metabolite protein links 26 - 50 of 68 in total